Assets
(4 total)
4Total Assets
1Approved
1Phase 3 / Filed
2Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
| Approved | ROS1Small molecule | Non-Small Cell Lung Cancer ROS1-Positive Non-Small Cell Lung Cancer | |
| Phase 3 | ALKSmall molecule | Non-Small Cell Lung Cancer | |
| Phase 1 | HER2Small molecule | Non-Small Cell Lung Cancer HER2-Mutant Non-Small Cell Lung Cancer | |
| Preclinical / Unstaged | —Small molecule | Non-Small Cell Lung Cancer ALK-Positive Non-Small Cell Lung Cancer |
Upcoming events
Research
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.